» Forgot username or password?
About Us
Private Client Group
Investment Banking
Fixed Income
Home > About Us > What's New
pre-loaded image pre-loaded image
Market Brief
(20-min delayed)

What's New

MRCC's Andre Uddin Honoured with Top StarMine Analyst Award

June 16, 2017

The StarMine awards has ranked one of MRCC's very own as number 1 in the 2017 Overall Analyst category for Top Stock Picker

Based on StarMine methodology, the Thomson Reuters Analyst Awards are globally recognized as the gold standard in objective measurement of sell-side analyst performance. The awards measure the performance of sell-side analysts based on the returns of their buy and sell recommendations relative to industry benchmarks; and the accuracy of their earnings estimates in 14 regions across the globe.

Mackie Research has consistently placed in the top 10 of various categories of StarMine awards for the last three years.

See more information on StarMine's quantitative analytics.

Globe and Mail Coverage

Top Stock Picker Ranking

Mackie Research spotlighted in Business In Focus magazine

May 24, 2017

Earlier this year, MRCC was offered an exciting opportunity to be featured in the May, 2017 issue of Business InFocus Magazine; a publication that is distributed to over 363,000 subscribers in North America. The focus of the article was developed through an exclusive interview with President, Geoff Whitlam. In this candid article, Geoff covers a range of topics from the climate of the financial industry, commoditization among banks and our long and storied history of professional experience.

Read the full feature

Interim results for Immunovaccine's DPX-Survivac get thumbs up at Mackie

April 4, 2017

Mackie Research Capital analyst Andre Uddin says Immunovaccine's (TSX:IMV) interim results for its phase 1b clinical study of its novel T-cell-activating immuno-oncology candidate, DPX-Survivac, are "what you want to see for efficacy".

Read more

Analyst Andre Uddin on Knight Therapeutics

Knight Therapeutics' (TSX:GUD) fourth quarter results bested his expectations, but Mackie Research Capital analyst Andre Uddin isn't quite ready to call the stock a buy yet.

This morning, Knight reported its fourth quarter and fiscal 2016 results. In the fourth quarter, the company earned $7.9-million on revenue of $1.8-million, a topline that was up from the $300,000 it reported in the same period last year

Read more

Theratechnologies is still undervalued, says Mackie Research

A better than expected quarter has Mackie Research Capital analyst Andre Uddin feeling good about Theratechnologies' (TSX:TH) prospects.

This morning, Theratechnologies reported its Q4 and fiscal 2016 results. In the fourth quarter, the company posted EBITDA of $2.81-million on revenue of $10.37-million, a topline that was up 15.2 per cent over the same period a year prior.


All your questions answered about preparing your 2016 personal income tax return


Click here for Tax information for the 2016 tax year

Click here for 2016 Income tax preparation checklist

Three small-cap oil and gas picks from Mackie Research - Globe and Mail

Mackie Research recently released a research report entitled "Under-leveraged, Undervalued Growth Stocks with Momentum in 2017."

The stocks Mackie selected each have market capitalizations of less than $100-million (Canadian), and may not be suitable for more risk-averse investors. Having said that, here are three oil and gas stocks that Mackie Research believes have strong potential for solid gains.


MRCC in the news - Syncordia Technologies is hugely undervalued, says Mackie Research

Some good news from Syncordia Technologies (TSXV:SYN) is confirming Mackie Research Capital analyst Nikhil Thadani's bullish take on the stock, says the analyst.

Yesterday, Syncordia announced that its wholly owned subsidiary, Health Services Integration, was "pushing through inititiatives" that will add over $1-million annually to the bottom line, annually. The company also said that Billing Solutions, which it owns 80 per cent of, was in the process of signing contracts that would add $300,000 in annualized EBITDA, and that its wholly owned subsidiary Paragon Billing would also be adding $300,000 in EBITDA annually, from new contracts.


Theratech and Aurinia top healthcare picks for 2017 at Mackie Research

His top picks for 2016, Intellipharmaceutics (Nasdaq:IPCI) and Knight Therapeutics (TSX:GUD) returned 35.4 per cent and 39.1 per cent, respectively, in a year that was historically tough.

Now, Mackie Research Capital analyst Andre Uddin has revealed his top two picks for 2017. Once again, the analyst's top picks include a Canadian company listed in the U.S. and one listed in Canada.

Click here to read more

Intertain Group's UK listing an important milestone, says Mackie

The long awaited listing of Jackpotjoy shares in the United Kingdom may begin to tighten the valuation gap between Intertain Group (TSX:IT) and its more expensive peers, says Mackie Research Capital analyst Nikhil Thadani… Read More

Copyright © 2000-2017, Mackie Research Capital Corporation, All rights reserved.
Member – Canadian Investor Protection Fund
membre – fonds canadien de protection des épargnants
Contact Us | Site Map | Your Privacy | Legal & Regulatory